Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS

HIV Clinical Trials

Volumn 8, Issue 4, 2007, Pages 235-245

  Badia Llach, Xavier ^a   Lizan L ^a   Magaz, S ^b   Alvarez Sanz C ^c   Green, J ^d   Serrano, D ^b  

^a IQVIA   (United States)

^b Health Outcomes Research Europe   (Spain)

^c Roche Farma SA   (Spain)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

Cost effectiveness analysis; Economics; Enfuvirtide; HIV

Indexed keywords

DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; HIV; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; PEPTIDE FRAGMENTS;

EID: 34548237587     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0804-235     Document Type: Article

References (36)

1. Fauci AS. Twenty-five years of HIV/AIDS. Science. 2006;313:409.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8(4):191-203.
4. de Bethune MP, Hertogs K. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr Med Res Opin. 2006;22(12):2603-2612.
5. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust. 2007;186:146-151.
6. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497-1503.
7. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother. 2006;58(2):235-242.
8. Clotet B. Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. AIDS Rev. 2004;6(3):123-130.
9. Moatti JR Spire B, Kazatchkine M. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south. AIDS. 2004;18:S55-61.
10. Sax PE. Updated DHHS treatment guidelines. AIDS Clin Care. 2006;18:105.
11. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3(5):371-378.
12. Ruane P, Lang J, DeJesus E, et al. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. HIV Clin Trials. 2006;7(5):229-236.
13. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
14. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
15. Cook J, Dasbach E, Coplan R Markson L, Yin D, Meibohm A. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses. 1999;15:499-508.
16. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201-207.
17. Bycott P, Taylor J. A comparison of smoothing techniques for CD4 data measured with error in a time dependent Cox proportional hazards models. Stat Med. 1998;17:2061-2077.
18. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991;114:798-802.
19. Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. J Acquir Immune Defic Syndr. 1991;4:795-804.
20. Simpson K, Hatziandreu EJ, Andersson F, Shakespeare A, Oleksy I, Tosteson AN. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries. Pharmacoeconomics. 1994;6:553-562.
21. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspective. Pharmacoeconomics. 1996;10:109-113.
22. Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care. 1998;4:1004-1012.
23. Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997;12:54-66.
24. Caro JJ, O'Brien JA, Migliaccio-Walle K, Raggio G. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. Pharmacoeconomics. 2001;19:95-104.
25. Hornberger J, Green J, Wintfeld N, et al. Cost-effectiveness of enfuvirtide for treatment experienced patients with HIV in Italy. HIV Clin Trials. 2005;6(2):92-102.
26. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
27. Consejo General de Colegios Oficiales de Farmacéuticos. PortalFarma.com. 2004. Available at: http://www.portalfarma.com
28. Santin Cerezales M. Estimating the costs of health care for patients infected with the human immunodeficiency virus in a university hospital in Catalonia. Rev Clin Esp. 2004;198:429-432.
29. Pinto JL, Lopez LC, Badia X, Coma A, Benavides A. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients]. Med Clin (Barc). 2000;114(Suppl 3):62-67.
30. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-450.
31. Biddle AK, Simpson N. Modelling the use of triple combination therapy in five countries: nevirapine, zidovudine, and didanosine. Value Health. 2000;3:186-201.
32. Hornberger J, Youle M, Beck EJ. Cost-effectiveness of enfuvirtide from UK health perpspective. Paper presented at: Ninth European AIDS Conference, 2003; Warsaw, Poland.
33. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340(21):1683-1684.
34. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39:69-77.
35. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16:334-343.
36. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824-831.